Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Virginia

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Awareness

For decades, general health and science communication has served as a foundational pillar of public knowledge, offering broad guidance on wellness, disease prevention, and the safe use of medications. This legacy of accessible information has empowered individuals to make informed decisions about their health, often focusing on lifestyle factors and common medical interventions. Within this framework, the safe administration of prescription drugs has always been a central concern, with emphasis on patient education and adherence to prescribed regimens. As the scope of health information has expanded, so too has the recognition that certain medications may carry specific, context-dependent risks that require more targeted awareness. One such area of evolving understanding involves the long-term use of bisphosphonates, a class of drugs widely prescribed for bone density management. While general health resources have historically addressed these medications in terms of their benefits for conditions like osteoporosis, a more nuanced perspective has emerged regarding potential complications in certain patient populations.

Bridging to Specific Risks: Fosamax and Osteonecrosis of the Jaw

This shift in focus naturally leads to a consideration of occupational and environmental factors that may influence individual exposure and risk. For instance, the legal and medical landscape now includes discussions around the statute of limitations for filing claims related to adverse outcomes, such as those associated with Fosamax use in Virginia. This transition from broad health education to specific, exposure-related concerns underscores the need for precise, context-aware guidance that bridges general knowledge with specialized legal and medical realities. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Understanding Osteonecrosis of the Jaw (ONJ) and Its Risk Factors

Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate therapy, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In clinical studies, most patients experienced relief of symptoms after discontinuing the drug, though a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Adequacy of Warnings

The mechanistic pathways linking Fosamax to ONJ involve the drug's action as a bisphosphonate, which inhibits osteoclast-mediated bone resorption. This suppression of bone turnover can impair the normal healing processes in the jaw, particularly after dental procedures or in the presence of infection. The resulting accumulation of microdamage and reduced blood supply to the jawbone may contribute to the development of necrotic bone lesions characteristic of ONJ. Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4) that describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and identifies known risk factors. However, the adequacy of these warnings in informing patients and healthcare providers about the specific risks and the need for dental evaluation before and during therapy may be subject to legal scrutiny, particularly in cases where patients developed ONJ without clear prior warning.

Legal Considerations: Statute of Limitations for Fosamax Claims in Virginia

For affected patients in Virginia, attorney-related considerations include the statute of limitations for filing a product liability claim. In Virginia, the statute of limitations for personal injury claims, including those related to defective drugs, is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical for patients who have developed ONJ after using Fosamax, as the time between exposure and documented harm can be variable. The onset of ONJ symptoms can occur from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), but the condition may also develop after longer periods of use, as the risk increases with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients should be aware that the clock for the statute of limitations may start ticking from the date of diagnosis or when the connection to Fosamax was recognized, not necessarily from the date of first exposure. In summary, Fosamax is associated with a risk of osteonecrosis of the jaw, with onset varying from days to months after starting treatment. The risk is increased by factors such as invasive dental procedures, cancer diagnosis, and longer duration of use. The prescribing information includes warnings about ONJ, but patients who have developed this condition should consult with an attorney to understand their legal rights and the applicable statute of limitations in Virginia.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Virginia?

In Virginia, the statute of limitations for personal injury claims, including those related to defective drugs, is generally two years from the date the injury was discovered or reasonably should have been discovered. This means the clock may start from the date of ONJ diagnosis or when the connection to Fosamax was recognized.

What are the known risk factors for developing osteonecrosis of the jaw from Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.